Journal of Drugs in Dermatology
JDD is a monthly, PubMed/MEDLINE-indexed peer-reviewed dermatology journal serving US dermatologists, residents, NPs, and PAs with complimentary subscriptions. It monetizes via institutional subscriptions, advertising, podcast sponsorship, CME activities, and a $89 digital inclusive dermatology atlas.
- Company typePrivate
- Founded2002
- HeadquartersNew York, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Journal of Drugs in Dermatology does
The Journal of Drugs in Dermatology (JDD) is a monthly, peer-reviewed, PubMed/MEDLINE-indexed dermatology journal and online resource founded in 2002 and operated by parent company SanovaWorks in New York. JDD serves a US-focused audience of dermatologists (MDs), dermatology residents, nurse practitioners, and physician assistants with complimentary individual subscriptions, and monetizes through institutional/library/corporate subscriptions, display advertising and podcast sponsorship (largely from pharmaceutical and device manufacturers), reprints and permissions, CME activities, and digital product sales.
The product portfolio is built around the core JDD journal and its growing archive of 1,000+ peer-reviewed articles spanning medical, aesthetic, and oncologic dermatology. It is complemented by The Full Spectrum of Dermatology: A Diverse and Inclusive Atlas — a digital edition with 1,000+ side-by-side images across 110+ conditions and all skin tones, sold for $89 — along with eJDD electronic access, a decade-long podcast hosted by Dr. Adam Friedman, accredited CME activities, webinars, video abstracts, case reports, and curated resource centers for pigmentary disorders, psoriasis, and oncodermatology.
JDD's go-to-market combines event-driven distribution (as official media partner at Skin of Color Update, ODAC Dermatology, and Las Vegas Derm Seminar), a community-led engagement model (CME, podcast, webinars, newsletters), and sales-led institutional and corporate subscription tiers. The diversified revenue mix, multi-format content platform, and unique skin-of-color atlas position JDD as a niche professional dermatology publisher with both advertising and recurring subscription economics.
Journal of Drugs in Dermatology firmographics
Firmographics- Name
- Journal of Drugs in Dermatology
- Legal name
- Journal of Drugs in Dermatology
- Website
- https://jddonline.com
- Company type
- Private
- Founded year
- 2002
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- JDD is a monthly, PubMed/MEDLINE-indexed peer-reviewed dermatology journal serving US dermatologists, residents, NPs, and PAs with complimentary subscriptions. It monetizes via institutional subscriptions, advertising, podcast sponsorship, CME activities, and a $89 digital inclusive dermatology atlas.
- Ownership category
- akta.pro rank
Where Journal of Drugs in Dermatology is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Journal of Drugs in Dermatology business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Revenue model
- Individual Subscriptions (Complimentary): Complimentary subscriptions for US dermatologists, dermatology residents, nurse practitioners, and physician assistants, generating audience reach that supports advertising and sponsorship revenue.
- Institutional, Library & Corporate Subscriptions: Paid institutional and corporate subscription tiers for academic libraries, hospital systems, and dermatology practices seeking broader access to JDD's content archive.
- Digital Product Sales (Atlas): Sale of The Full Spectrum of Dermatology: A Diverse and Inclusive Atlas digital edition for $89.00, targeting educators, dermatologists, and trainees.
- Podcast Sponsorship: Sponsored episodes and underwriting opportunities within the JDD Podcast, reaching dermatology professionals.
- Advertising & Media Kit: Display advertising and branded content opportunities across the journal's online platform, reaching dermatology professionals.
- Reprints & Permissions: Sale of article reprints and licensing of figures/tables for use in manuscripts, presentations, and other publications.
- CME Activities: Continuing medical education content that may generate revenue through accredited CME programs and sponsored educational activities.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Annual | Complimentary individual subscription for qualifying US dermatology professionals |
| One time/ perpetual license | Pay-as-you-go | The Full Spectrum of Dermatology: A Diverse and Inclusive Atlas Digital Edition |
| Subscription | Annual | Institutional, Library & Corporate Subscriptions |
Go-to-market motion3 records
Distribution channels6 records
Marketing channels12 records
Journal of Drugs in Dermatology product offering
Product offeringCore offering
JDD is a monthly peer-reviewed, PubMed/MEDLINE-indexed dermatology journal that publishes research on drugs, devices, and treatment methods in dermatology. It complements its editorial content with a digital inclusive dermatology atlas (1,000+ images across skin tones), CME activities, podcasts, webinars, and video abstracts, distributing access through complimentary individual subscriptions for US dermatology professionals and paid institutional/corporate subscriptions.
Product overview
The Journal of Drugs in Dermatology (JDD) is a monthly peer-reviewed, PubMed/MEDLINE-indexed dermatology journal and online resource operated by SanovaWorks. The product portfolio centers on the core JDD journal, supplemented by the Inclusive Derm Atlas (a digital image atlas with 1,000+ inclusive dermatology images), eJDD electronic access, CME activities, podcasts, webinars, and video abstracts. The journal offers curated resource centers for pigmentary disorders and psoriasis, and publishes case reports and supplements. Complimentary subscriptions are available for US dermatologists, residents, nurse practitioners, and physician assistants.
Differentiator
Problem solved
Functional benefit
Brands
- The Full Spectrum of Dermatology: A Diverse and Inclusive Atlas: A comprehensive dermatology image atlas showcasing skin conditions across all skin tones, published as a digital edition and online gallery with 1,000+ images and over 110 dermatologic conditions
- eJDD
- JDD Podcast
- JDD Corner
- DermEdge
Products and services
- Journal of Drugs in Dermatology (JDD) Monthly peer-reviewed, PubMed/MEDLINE-indexed dermatology journal publishing research on drugs, devices, and treatment methods. Distributed via complimentary individual subscriptions to US dermatologists, residents, NPs, and PAs, and via paid institutional and corporate subscriptions.
- The Full Spectrum of Dermatology: A Diverse and Inclusive Atlas (Digital Edition) Digital dermatology atlas with 1,000+ side-by-side inclusive images covering 110+ dermatologic conditions across all skin tones, with clinical commentary. Sold as a $89.00 digital edition targeting dermatology educators, dermatologists, and trainees.
- JDD CME Activities Accredited continuing medical education activities for dermatology professionals (dermatologists, NPs, PAs), including free CME opportunities that support license renewal and professional development.
- JDD Podcast Long-running dermatology podcast hosted by Dr. Adam Friedman, featuring expert interviews, clinical pearls, and evidence-based updates across aesthetic, medical, and oncologic dermatology topics. Distributed on major podcast platforms with sponsored episodes available.
- JDD Webinars Live and on-demand webinar series featuring dermatology faculty discussing drug therapies, devices, and clinical topics for dermatology professionals and advanced practice providers.
Quantifiable outcome
- 1,000+ dermatology articles published
- +3 more outcomes
Companies that use Journal of Drugs in Dermatology
Customer profileNamed customers5 records
Segments6 records
Ideal customer profiles3 records
Journal of Drugs in Dermatology technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Journal of Drugs in Dermatology partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core, flagship and minor.
- SanovaWorkscoreSanovaWorks is the parent company and publisher of the Journal of Drugs in Dermatology. It also publishes the Derm In-Review, Pigmentary Disorders Express (PDE), Next Steps in Derm, and other dermatology education platforms.
- Skin of Color Update (SOCU)flagshipJDD is the official media partner for the Skin of Color Update (SOCU) annual conference, publishes the SOCU poster abstract eSupplement (70+ abstracts), and promotes the conference through its platform and editorial coverage.
- ODAC Dermatology, Aesthetic & Surgical ConferencecoreJDD is a conference partner for ODAC Dermatology, Aesthetic & Surgical Conference, promoting the event and covering it editorially.
- Las Vegas Derm SeminarcoreJDD is a conference partner for the Las Vegas Derm Seminar, providing editorial coverage and promoting the conference to its audience.
- MedscapeLive!coreJDD editorial team collaborates with MedscapeLive! and Forefront Dermatology on the DermEdge free CME platform, a podcast-style on-demand CME series for dermatology professionals.
- Forefront DermatologycoreForefront Dermatology partnered with MedscapeLive! to develop DermEdge, a free CME platform featuring JDD editorial content and dermatology faculty.
- Educational Testing & Assessment SystemscoreCo-publishing partner for The Full Spectrum of Dermatology: A Diverse and Inclusive Atlas, developed by co-editors Misty Eleryan, MD, MS and Adam Friedman, MD.
- Next Steps in DermminorNext Steps in Derm republishes JDD's inclusive atlas content series ('The Many Faces of') and cross-promotes dermatology educational content, reaching an extended trainee and practitioner audience.
- USA TODAYminorUSA TODAY featured The Full Spectrum of Dermatology: A Diverse and Inclusive Atlas in an article about how dermatologists are addressing the paucity of skin of color images in dermatology education.
- Dermatology TimesminorDermatology Times has covered multiple JDD studies, including research on Malassezia folliculitis, vitiligo comorbidities, hydroquinone, and hyperhidrosis, lending editorial credibility.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Journal of Drugs in Dermatology competitors and assessment
Company assessmentDirect peers
- Skin Pharmacology and Physiology: Skin Pharmacology and Physiology is a Karger peer-reviewed journal focused on skin pharmacology and physiology, with thematic overlap to JDD's drug-focused editorial positioning.
- Journal of the American Academy of Dermatology (JAAD): JAAD is the flagship peer-reviewed dermatology journal from the American Academy of Dermatology and the most direct competitor to JDD, publishing original research, reviews, and CME content for the same dermatology professional audience.
- Clinical, Cosmetic and Investigational Dermatology: Clinical, Cosmetic and Investigational Dermatology is an open-access, peer-reviewed Dove Press journal covering clinical and aesthetic dermatology, directly competitive with JDD's medical and aesthetic dermatology article mix.
- Dermatologic Therapy: Dermatologic Therapy is a peer-reviewed Wiley journal focused on therapeutics in dermatology, overlapping directly with JDD's drug- and device-oriented editorial scope and serving a similar clinician audience.
- JAMA Dermatology: JAMA Dermatology is a high-impact peer-reviewed dermatology journal from the JAMA Network that competes head-to-head with JDD for clinical research submissions, readership, and dermatology advertising revenue.
- British Journal of Dermatology: British Journal of Dermatology is a leading international peer-reviewed dermatology journal published by Oxford University Press, competing with JDD for global authors, citations, and institutional library subscriptions.
Broad incumbents
- Dermatology Times: Dermatology Times is a long-established dermatology trade publication covering clinical news, drug updates, and practice management for the same dermatologist audience, often covering JDD studies and competing for the same pharma ad budget.
- Healio Dermatology: Healio Dermatology delivers peer-reviewed news, CME, and conference coverage to dermatologists and is a recurring media outlet that covers JDD research, competing for dermatology HCP audience attention and sponsorship dollars.
- MDedge Dermatology: MDedge Dermatology provides dermatology clinical news, conference coverage, and CME for practicing dermatologists, sitting in the same advertising- and sponsorship-supported peer-reviewed media space as JDD.
Others
- Medscape Dermatology: Medscape Dermatology is a clinician portal providing dermatology news, CME, and reference content; JDD already partners with MedscapeLive via the DermEdge CME platform, making it both an indirect competitor and a channel for distributing JDD content.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Journal of Drugs in Dermatology social profiles
Digital presenceJournal of Drugs in Dermatology compliance and trust
Trust signalCompliance1 record
Journal of Drugs in Dermatology financial estimates
Financial estimateRevenue estimate
Valuation estimate
Journal of Drugs in Dermatology leadership team
Management profileNumber of profiles
Profiles2 records
Journal of Drugs in Dermatology funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Journal of Drugs in Dermatology M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Journal of Drugs in Dermatology
What does Journal of Drugs in Dermatology do?
JDD is a monthly peer-reviewed, PubMed/MEDLINE-indexed dermatology journal that publishes research on drugs, devices, and treatment methods in dermatology. It complements its editorial content with a digital inclusive dermatology atlas (1,000+ images across skin tones), CME activities, podcasts, webinars, and video abstracts, distributing access through complimentary individual subscriptions for US dermatology professionals and paid institutional/corporate subscriptions.
Is Journal of Drugs in Dermatology a public or private company?
Journal of Drugs in Dermatology is a private company. It is classified as corporate owned and is currently operating.
When was Journal of Drugs in Dermatology founded?
Journal of Drugs in Dermatology was founded in 2002. It employs 51 to 100 people.
Where is Journal of Drugs in Dermatology based?
Journal of Drugs in Dermatology is headquartered in New York, United States, in the North America region.
How does Journal of Drugs in Dermatology make money?
Seven revenue lines are on record. Individual Subscriptions (Complimentary) is the primary driver. The others are institutional, Library & Corporate Subscriptions, digital Product Sales (Atlas), podcast Sponsorship, advertising & Media Kit, reprints & Permissions and CME Activities.
Who are Journal of Drugs in Dermatology's main competitors?
Direct peers on record are Skin Pharmacology and Physiology, Journal of the American Academy of Dermatology (JAAD), Clinical, Cosmetic and Investigational Dermatology, Dermatologic Therapy, JAMA Dermatology and British Journal of Dermatology. Broad incumbents are Dermatology Times, Healio Dermatology and MDedge Dermatology. Medscape Dermatology is listed as an others.
Does Journal of Drugs in Dermatology have an API?
No public API is recorded for Journal of Drugs in Dermatology.